Literature DB >> 21142288

Comparing methods of data synthesis: re-estimating parameters of an existing probabilistic cost-effectiveness model.

Mark Oppe1, Maiwenn Al, Maureen Rutten-van Mölken.   

Abstract

BACKGROUND: Cost-effectiveness models should always be amendable to updating once new data on important model parameters become available. However, several methods of synthesizing data exist and the choice of method may affect the cost-effectiveness estimates.
OBJECTIVES: To investigate the impact of the different methods of meta-analysis on final estimates of cost effectiveness from a probabilistic Markov model for chronic obstructive pulmonary disease (COPD).
METHODS: We compared four different methods to synthesize data for the parameters of a cost-effectiveness model for COPD: frequentist and Bayesian fixed-effects (FE) and random-effects (RE) meta-analyses. These methods were applied to obtain new transition probabilities between stable disease states and new event probabilities.
RESULTS: The four methods resulted in different estimates of probabilities and their standard errors (SE). The effects of using different synthesis techniques were most prominent in the estimation of the SEs. We found up to 9-fold differences in SEs of the exacerbation probabilities and up to almost 3-fold differences in SEs of the transition probabilities. We found that the frequentist FE model produced the lowest SEs, whereas the Bayesian RE model produced the highest for all parameters. The estimates of differences between treatments in total costs, QALYs and cost-effectiveness acceptability curves (CEAC) also varied depending on the synthesis method. The CEAC was 15% lower with a Bayesian RE model than with any of the other models.
CONCLUSIONS: Health economic modellers should be aware that the choice of synthesis technique can affect resulting model parameters considerably, which can in turn affect estimates of cost effectiveness and the uncertainty around them.

Entities:  

Mesh:

Year:  2011        PMID: 21142288     DOI: 10.2165/11539870-000000000-00000

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN: 1170-7690            Impact factor:   4.981


  15 in total

1.  Quantifying heterogeneity in a meta-analysis.

Authors:  Julian P T Higgins; Simon G Thompson
Journal:  Stat Med       Date:  2002-06-15       Impact factor: 2.373

Review 2.  Measuring inconsistency in meta-analyses.

Authors:  Julian P T Higgins; Simon G Thompson; Jonathan J Deeks; Douglas G Altman
Journal:  BMJ       Date:  2003-09-06

Review 3.  Economic modeling in chronic obstructive pulmonary disease.

Authors:  Maureen Rutten-van Mölken; Todd A Lee
Journal:  Proc Am Thorac Soc       Date:  2006-09

4.  Meta-analysis in clinical trials.

Authors:  R DerSimonian; N Laird
Journal:  Control Clin Trials       Date:  1986-09

5.  Probabilistic Markov model to assess the cost-effectiveness of bronchodilator therapy in COPD patients in different countries.

Authors:  Jan B Oostenbrink; Maureen P M H Rutten-van Mölken; Brigitta U Monz; J Mark FitzGerald
Journal:  Value Health       Date:  2005 Jan-Feb       Impact factor: 5.725

6.  Smoking cessation and lung function in mild-to-moderate chronic obstructive pulmonary disease. The Lung Health Study.

Authors:  P D Scanlon; J E Connett; L A Waller; M D Altose; W C Bailey; A S Buist; D P Tashkin
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

7.  A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease.

Authors:  R Casaburi; D A Mahler; P W Jones; A Wanner; Pedro G San; R L ZuWallack; S S Menjoge; C W Serby; T Witek
Journal:  Eur Respir J       Date:  2002-02       Impact factor: 16.671

8.  Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium.

Authors:  W Vincken; J A van Noord; A P M Greefhorst; Th A Bantje; S Kesten; L Korducki; P J G Cornelissen
Journal:  Eur Respir J       Date:  2002-02       Impact factor: 16.671

9.  Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD.

Authors:  V Brusasco; R Hodder; M Miravitlles; L Korducki; L Towse; S Kesten
Journal:  Thorax       Date:  2003-05       Impact factor: 9.139

10.  Modelling the 5-year cost effectiveness of tiotropium, salmeterol and ipratropium for the treatment of chronic obstructive pulmonary disease in Spain.

Authors:  Maureen P M H Rutten-van Mölken; Jan B Oostenbrink; Marc Miravitlles; Brigitta U Monz
Journal:  Eur J Health Econ       Date:  2007-03-17
View more
  3 in total

1.  A choice that matters? Smulation study on the impact of direct meta-analysis methods on health economic outcomes.

Authors:  Pepijn Vemer; Maiwenn J Al; Mark Oppe; Maureen P M H Rutten-van Mölken
Journal:  Pharmacoeconomics       Date:  2013-08       Impact factor: 4.981

2.  Mix and match. A simulation study on the impact of mixed-treatment comparison methods on health-economic outcomes.

Authors:  Pepijn Vemer; Maiwenn J Al; Mark Oppe; Maureen P M H Rutten-van Mölken
Journal:  PLoS One       Date:  2017-02-02       Impact factor: 3.240

Review 3.  Current recommendations on the estimation of transition probabilities in Markov cohort models for use in health care decision-making: a targeted literature review.

Authors:  Elena Olariu; Kevin K Cadwell; Elizabeth Hancock; David Trueman; Helene Chevrou-Severac
Journal:  Clinicoecon Outcomes Res       Date:  2017-09-01
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.